Fig. 7From: Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-lowDifferent expression patterns of critical immunotherapeutic biomarkers in HER2low TNBC and HER2neg TNBC. (A) Violin plot shows the expression levels of key immunotherapeutic biomarkers in the two TNBC groups. See Additional file 14: Table S7 for details. (B) Color-coded UMAPs for expression levels (gray to red) of PDCD1 and CD274 in two TNBC groups. (C) Correlations between ERBB2 expression and immunotherapeutic targets (CD274, CTLA4, CD47, CDK6, DDR2, PDCD1), using Spearman correlation analysis; P < 0.05 indicates statistical significanceBack to article page